Bepotastine controlled-release - Hanlim Pharmaceutical

Drug Profile

Bepotastine controlled-release - Hanlim Pharmaceutical

Alternative Names: Bepotastine sustained-release; HL 151

Latest Information Update: 23 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Antihistamines; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Perennial allergic rhinitis

Most Recent Events

  • 01 Feb 2016 Hanlim Pharm initiates enrolment in a phase I trail in Healthy volunteers in South Korea (NCT02686294)
  • 01 Jan 2016 Phase-I clinical trials in Perennial allergic rhinitis (In volunteers) in South Korea (PO, Controlled-release) (NCT02682745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top